Novo Nordisk is collaborating with the Massachusetts Institute of Technology to conduct research on new drug delivery devices for peptides, according to a Pipeline Review report.
Here are five takeaways:
1. Novo Nordisk's research facilities in Denmark will join forces with a team of MIT researchers, co-led by Giovanni Traverso, MBBCh, PhD, and Prof. Robert S. Langer.
2. Dr. Traverso is a gastroenterologist at Massachusetts General Hospital and instructor of medicine at Harvard Medical School, both in Boston.
3. He is a research affiliate of the Langer Laboratory at MIT.
4. Through the collaboration, MIT and Novo Nordisk aim to develop the next generation of drug delivery devices as an alternative to parenteral or injection-based delivery of peptides.
5. The initial term of the collaboration is three years.